{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpsychedelic-spotlight.simplecast.com%2Fepisodes%2Ftimothy-ko-UDkXvd_C","width":444,"version":"1.0","type":"rich","title":"Timothy Ko, Entheon Biomedical","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/bebecc7d-bab7-47e7-be66-437a184e067d/8afaf229-7aa9-4031-aa6d-35c4957ef16e/simplecast-cover.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/558260bf-61d7-410e-af63-c9b506f902a9\" height=\"200\" width=\"100%\" title=\"Timothy Ko, Entheon Biomedical\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions."}